Description of Neuronetics Inc's Business Segments

Neuronetics Inc. specializes in the development of innovative technologies for the treatment of neurological and psychiatric conditions, primarily focusing on Depression and other mood disorders. Their flagship product utilizes Transcranial Magnetic Stimulation (TMS) technology, specifically designed to provide non-invasive treatment options for patients suffering from various mental health issues. Below is a detailed breakdown of the segments, products, and services offered by Neuronetics:

1. Segments
Neuronetics primarily operates in the following segments:

- Healthcare Providers: This includes hospitals, outpatient clinics, and mental health facilities that utilize Neuronetics technologies to treat patients with depression and other mood disorders.

- Patients: Individuals suffering from Major Depressive Disorder (MDD) and other related conditions who seek alternative treatment options often overlooked or inadequately addressed by traditional therapies.

- Research Institutions: Collaborates with academic and clinical research organizations to explore new applications of TMS and contribute to the body of scientific knowledge regarding neurological treatments.

Products
Neuronetics’ product lineup is centered around its TMS therapy systems. The most prominent products include:

a. NeuroStar TMS Therapy System
- Overview: This is the flagship product and the first FDA-cleared TMS system for the treatment of MDD in adults who have failed to respond to previous antidepressant medications.
- Technology: Employs magnetic fields to stimulate nerve cells in the brain, which is believed to help improve symptoms of depression.
- Features:
- Non-invasive and well-tolerated with favorable side effect profiles compared to traditional medications.
- Offers a personalized treatment protocol tailored to each patient’s specific needs.
- Provides real-time data for monitoring treatment progress and outcomes.

Services
In addition to its products, Neuronetics offers several services aimed at facilitating the adoption and effective use of its TMS technology:

a. Training and Education
- Provider Training: Comprehensive training programs for healthcare providers on operating the NeuroStar system and delivering TMS therapy safely and effectively.
- Patient Education: Resources and support for patients to better understand TMS therapy, including its benefits, process, and potential outcomes.

b. Clinical Support
- Consultative Services: Offering expertise and guidance to healthcare facilities on how to integrate TMS therapy into their existing treatment protocols.
- Clinical Data Collection: Support in gathering and analyzing clinical outcomes data to enhance treatment effectiveness and establish best practices in the deployment of TMS therapy.

c. Patient Support
- Access Programs: Resources for patients to understand insurance coverage and financial assistance options for those in need of TMS therapy.
- Follow-Up Care: Continuous engagement with patients post-treatment to assess ongoing mental health and satisfaction with TMS therapy.

d. Research and Development Services
- Clinical Trials: Participation in and support of clinical trials focusing on expanding the use of TMS technology for various neuropsychiatric disorders beyond MDD, such as anxiety disorders, PTSD, and OCD.
- Innovation Pipeline: Ongoing research initiatives aimed at developing new TMS applications and enhancements to existing technologies.

Summary
Neuronetics Inc. is dedicated to advancing the treatment landscape for major depressive disorder and other mental health conditions through its pioneering TMS technology. By facilitating effective, non-invasive therapy options, providing comprehensive training and support for healthcare providers, and staying committed to research and innovation, Neuronetics plays a vital role in enhancing mental health care options for patients in need.

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Composition of Neuronetics Inc Revenues by Segments


Service	63.04 %	of total Revenue
Product Category U S	100.21 %	of total Revenue
Product Category U S Revenues NeuroStar Advanced Therapy System	9.38 %	of total Revenue
Product Category U S Revenues Treatment sessions	26.71 %	of total Revenue
Product Category U S Revenues Clinic revenue	63.04 %	of total Revenue
Product Category U S Revenues Other	1.09 %	of total Revenue
Product Category International	0.67 %	of total Revenue
Product Category International Revenues NeuroStar Advanced Therapy System	0.13 %	of total Revenue
Product Category International Revenues Treatment sessions	0.36 %	of total Revenue
Product Category International Revenues Other	0.17 %	of total Revenue
segment	100.88 %	of total Revenue
Med Device segment	37.84 %	of total Revenue
Clinic Service segment	63.04 %	of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments	Revenues (in millions $)	% (of total Revenues)
Service	21.53	63.04 %
Product Category U S	34.23	100.21 %
Product Category U S Revenues NeuroStar Advanced Therapy System	3.20	9.38 %
Product Category U S Revenues Treatment sessions	9.12	26.71 %
Product Category U S Revenues Clinic revenue	21.53	63.04 %
Product Category U S Revenues Other	0.37	1.09 %
Product Category International	0.23	0.67 %
Product Category International Revenues NeuroStar Advanced Therapy System	0.05	0.13 %
Product Category International Revenues Treatment sessions	0.12	0.36 %
Product Category International Revenues Other	0.06	0.17 %
segment	34.45	100.88 %
Med Device segment	12.93	37.84 %
Clinic Service segment	21.53	63.04 %
Total	34.15	100 %

Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment	Y/Y Revenue %	Q/Q Revenue %
Service	15.38 %	-
Product Category U S	8.71 %	-
Product Category U S Revenues NeuroStar Advanced Therapy System	12.54 %	-
Product Category U S Revenues Treatment sessions	-5.1 %	-
Product Category U S Revenues Clinic revenue	15.38 %	-
Product Category U S Revenues Other	1.64 %	-
Product Category International	-53.66 %	-
Product Category International Revenues NeuroStar Advanced Therapy System	-71.95 %	-
Product Category International Revenues Treatment sessions	-17.33 %	-
Product Category International Revenues Other	-67.42 %	-
segment	7.75 %	-
Med Device segment	-2.94 %	-
Clinic Service segment	15.38 %	-
Total	7.61 %	-

Q1 three months ended (Mar 31 2026)
Income by Business Segments	Income (in millions $)	% (Profit Margin)
segment	16.15	46.89 %
Total	-10.78	-

Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment	Y/Y Income %	Q/Q Income %
segment	2.64 %	-
Total	-	-

Annual Report on Neuronetics Inc Divisions, Sales by Country


Service	58.65 %	of total Revenue
Product Category U S	98.48 %	of total Revenue
Product Category U S Revenues NeuroStar Advanced Therapy System	9.61 %	of total Revenue
Product Category U S Revenues Treatment sessions	29.21 %	of total Revenue
Product Category U S Revenues Clinic revenue	58.65 %	of total Revenue
Product Category U S Revenues Other	1.01 %	of total Revenue
Product Category International	2.1 %	of total Revenue
Product Category International Revenues NeuroStar Advanced Therapy System	0.86 %	of total Revenue
Product Category International Revenues Treatment sessions	0.73 %	of total Revenue
Product Category International Revenues Other	0.5 %	of total Revenue
segment	100.57 %	of total Revenue
Med Device segment	41.93 %	of total Revenue
Clinic Service segment	58.65 %	of total Revenue

Twelve months ended 2025
STIM s Annual Revenue by Geography and Business Segments	Sales (in millions $)	% (of total Sales)
Service	86.98	58.65 %
Product Category U S	146.05	98.48 %
Product Category U S Revenues NeuroStar Advanced Therapy System	14.26	9.61 %
Product Category U S Revenues Treatment sessions	43.32	29.21 %
Product Category U S Revenues Clinic revenue	86.98	58.65 %
Product Category U S Revenues Other	1.49	1.01 %
Product Category International	3.11	2.1 %
Product Category International Revenues NeuroStar Advanced Therapy System	1.28	0.86 %
Product Category International Revenues Treatment sessions	1.09	0.73 %
Product Category International Revenues Other	0.75	0.5 %
segment	149.16	100.57 %
Med Device segment	62.18	41.93 %
Clinic Service segment	86.98	58.65 %
Total	148.31	100 %

Twelve months ended 2025
STIM s Annual Income by Country and Business Segments	Income (in millions $)	% (Profit Margin)
segment	72.31	48.48 %
Total	-39.14	-

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments	% Y/Y Sales Growth	% Y/Y Income Growth
Service	1856.74 %	-
Product Category U S	101.48 %	-
Product Category U S Revenues NeuroStar Advanced Therapy System	-6.6 %	-
Product Category U S Revenues Treatment sessions	-14.78 %	-
Product Category U S Revenues Clinic revenue	1856.74 %	-
Product Category U S Revenues Other	-23.2 %	-
Product Category International	29.43 %	-
Product Category International Revenues NeuroStar Advanced Therapy System	54.48 %	-
Product Category International Revenues Treatment sessions	77.49 %	-
Product Category International Revenues Other	-22.64 %	-
segment	99.17 %	33.51 %
Med Device segment	-11.73 %	-
Clinic Service segment	1856.74 %	-
Total	99.98 %	-
Product Category U S Revenue	-	-
Product Category U S Revenue NeuroStar Advanced Therapy System	-	-
Product Category U S Revenue Treatment sessions	-	-
Product Category U S Revenue Clinic revenue	-	-
Product Category U S Revenue Other	-	-
Product Category International Revenue	-	-
Product Category International Revenue NeuroStar Advanced Therapy System	-	-
Product Category International Revenue Treatment sessions	-	-
Product Category International Revenue Other	-	-
Medical Device	-	-

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.